

- 1) A contraindication for Ampyra™ applies to which of the following patients?
 - a. A 50-year old woman with a history of seizures.
 - b. A 35-year old man with a creatinine clearance less than 50 mL/min.
 - c. A 42-year old man with a creatinine clearance less than 30 mL/min.
 - d. Both A and B
 - e. Both A and C
- 2) It is important to tell a patient who is starting Gilenya™ if he or she stops taking the medication for _____, they need to be monitored by a physician when restarting this medication.
 - a. 3 days
 - b. 1 week
 - c. 2 weeks
 - d. 1 month
- 3) Which statement about Viibryd™ is NOT true?
 - a. The dose must be titrated.
 - b. Viibryd™ should not be taken with food.
 - c. Patients are at an increased risk of bleeding when taking anticoagulants along with Viibryd™.
 - d. Viibryd™ should not be taken with MAOIs.
- 4) What is the difference between Byetta™ and Victoza™?
 - a. Victoza™ is an oral tablet. Byetta™ is for subcutaneous injection.
 - b. Byetta™ is dosed twice daily. Victoza™ is dosed once daily.
 - c. Victoza™ can be taken without regard to meals. Byetta™ must be taken with meals.
 - d. An increase in pancreatitis has been seen in patients taking Byetta™ but not Victoza™.
 - e. Both B and C.
- 5) Which two medications must be discarded 30 days after opening the original container?
 - a. Edarbi™ and Carbaglu™
 - b. Carbaglu™ and Pradaxa™
 - c. Pradaxa™ and Lastacraft™
 - d. Edarbi™ and Lastacraft™
- 6) True or False. Egrifta™ is supplied in powder vials. 1 vial contains one- 2mg dose.
 - a. True
 - b. False
- 7) If a patient taking Natazia™ misses a dose by more than _____, a back-up method of contraception must be used for _____.
 - a. 3 days; 7 days
 - b. 24 hours; 9 days
 - c. 2 days; 2 weeks
 - d. 12 hours; 9 days
- 8) True or False. Ella™ must be taken within 72 hours of unprotected intercourse.
 - a. True
 - b. False
- 9) Which is an important counseling point for Edarbi™?
 - a. Discard 30 days after opening original container.
 - b. Take with food.
 - c. Do not take if you are pregnant or plan to become pregnant.
 - d. Monitor weight.
- 10) Treatment with Natroba™ can be repeated in _____ if live lice are still seen.
 - a. 3 days
 - b. 2 weeks
 - c. 7 days
 - d. 5 days

KPERF Continuing Education Hours

This issue of *The Kentucky Pharmacist Journal* only contains one continuing education article. We will place an extra continuing education article in an upcoming issue of the journal. You will still be able to obtain 15 hours of continuing education through KPERF this year.

This activity is a FREE service to members of the Kentucky Pharmacists Association. The fee for non-members is \$30. The fee for duplicate certificates is \$5. Please send a self addressed, stamped envelope to KPERF, 1228 US 127 South, Frankfort, KY 40601.

Expiration Date: May 15, 2014

Successful Completion: Score of 80% will result in 1.0 contact hour or 0.10 CEUs. Participants who score less than 80% will be notified and permitted one re-examination.

**May 2011– New Medications You May Be Seeing in Your Pharmacy
TECHNICIANS ANSWER SHEET. Not ACPE approved for Technicians.**

Name _____ KY Cert. # _____

Address _____

PLEASE CIRCLE THE APPROPRIATE ANSWERS:

- | | | | | |
|--------------|--------------|------------|------------|-------------|
| 1. A B C D E | 3. A B C D | 5. A B C D | 7. A B C D | 9. A B C D |
| 2. A B C D | 4. A B C D E | 6. A B | 8. A B | 10. A B C D |

Met my educational needs	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Figures and tables were useful	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Achieve the stated objectives	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Posttest was appropriate	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Was well written	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Commercial bias was present	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Is relevant to my practice	<input type="checkbox"/> Yes	<input type="checkbox"/> No			

I hereby certify that I completed this self-study program independently and without assistance from any other party.

Signature _____ Date _____

**May 2011– New Medications You May Be Seeing in Your Pharmacy
Universal Activity # 0143-0000-11-005-H01-P
PHARMACISTS ANSWER SHEET**

Name _____ KY Lic. # _____

Address _____

PLEASE CIRCLE THE APPROPRIATE ANSWERS:

- | | | | | |
|--------------|--------------|------------|------------|-------------|
| 1. A B C D E | 3. A B C D | 5. A B C D | 7. A B C D | 9. A B C D |
| 2. A B C D | 4. A B C D E | 6. A B | 8. A B | 10. A B C D |

Information presented in the activity:

Met my educational needs	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Figures and tables were useful	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Achieve the stated objectives	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Posttest was appropriate	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Was well written	<input type="checkbox"/> Yes	<input type="checkbox"/> No	Commercial bias was present	<input type="checkbox"/> Yes	<input type="checkbox"/> No
Is relevant to my practice	<input type="checkbox"/> Yes	<input type="checkbox"/> No			

Unmet Objectives: _____
I hereby certify that I completed this self-study program independently and without assistance from any other party.

Signature _____ Date _____



The Kentucky Pharmacy Education & Research Foundation is accredited by The Accreditation Council for Pharmacy Education as a provider of continuing Pharmacy education.